ZambiaTuberculosis profile
Population  2017 17 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 5 (2.9–7.7) 30 (17–45)
Mortality (HIV+TB only) 13 (8.2–19) 76 (48–110)
Incidence  (includes HIV+TB) 62 (40–88) 361 (234–514)
Incidence (HIV+TB only) 36 (23–52) 210 (135–302)
Incidence (MDR/RR-TB)** 1.9 (0.67–3.8) 11 (3.9–22)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 3.6 (3.2–3.9) 20 (16–25) 24 (18–30)
Males 4 (3.6–4.3) 34 (24–44) 38 (26–49)
Total 7.5 (6.5–8.5) 54 (34–74) 62 (40–88)
TB case notifications, 2017  
Total cases notified 37 203
Total new and relapse 36 010
          - % tested with rapid diagnostics at time of diagnosis 28%
          - % with known HIV status 93%
          - % pulmonary 84%
          - % bacteriologically confirmed among pulmonary 53%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 58% (41–90)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.3 (0.17–0.46)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 20 362 59%
          - on antiretroviral therapy 18 341 90%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 300
(850–1 800)
Estimated % of TB cases with MDR/RR-TB 1.1% (0.34–2.3) 18% (12–26)  
% notified tested for rifampicin resistance 23% 9% 10 591
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 546, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 270, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 88% 38 326
Previously treated cases, excluding relapse, registered in 2016 79% 1 827
HIV-positive TB cases registered in 2016 86% 21 655
MDR/RR-TB cases started on second-line treatment in 2015 60% 99
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 18%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
3.8% (3.5–4.2)
TB financing, 2018  
National TB budget (US$ millions) 38
Funding source: 28% domestic, 52% international, 20% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-10-17 Data: www.who.int/tb/data